DongKoo Bio & Pharma Co., Ltd. (KOSDAQ:006620)
3,920.00
-205.00 (-4.97%)
At close: Jun 19, 2026
DongKoo Bio & Pharma Revenue
DongKoo Bio & Pharma had revenue of 58.06B KRW in the quarter ending March 31, 2026, a decrease of -1.04%. This brings the company's revenue in the last twelve months to 242.08B, down -0.68% year-over-year. In the year 2025, DongKoo Bio & Pharma had annual revenue of 242.69B, down -2.64%.
Revenue (ttm)
242.08B
Revenue Growth
-0.68%
P/S Ratio
0.44
Revenue / Employee
599.20M
Employees
404
Market Cap
106.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 242.69B | -6.59B | -2.64% |
| Dec 31, 2024 | 249.27B | 33.59B | 15.57% |
| Dec 31, 2023 | 215.69B | 20.70B | 10.62% |
| Dec 31, 2022 | 194.99B | 39.84B | 25.68% |
| Dec 31, 2021 | 155.15B | 15.93B | 11.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ahn-Gook Pharmaceutical | 330.05B |
| Cosmax Nbt | 308.56B |
| H.PIO | 266.01B |
| Kyung Dong Pharmaceutical | 198.27B |
| HYUNDAI BIOLAND | 135.04B |
| WITHUS PHARMACEUTICAL Co.,LTD. | 108.89B |
| OPTUS Pharmaceutical | 91.62B |
| KOREA PHARMA | 91.42B |